Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 3M COMMM · Entity 1275 | EVP & Chief Info Digital Off | February 02, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
3M CO
Report date February 02, 2026 · Filed February 18, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,024.9451 |
Reported balance
After 2026-02-02 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-02-02 · Tax withholding · Disposed 4,793.011 · Balance 13,024.9451 F1: The number of shares previously reported as being withheld for the payment of taxes was estimated. This amendment is being filed to update the Form 4 with the actual number of shares withheld. |
Filing footnotes · ownership attribution and instrument terms
F1: The number of shares previously reported as being withheld for the payment of taxes was estimated. This amendment is being filed to update the Form 4 with the actual number of shares withheld.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ST JUDE MEDICAL, LLC
Report date January 04, 2017 · Filed January 06, 2017
Section 16 reporting ended · disclosed 2017-01-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 1
1 source rowRow 1 · 2017-01-04 · Disposition to issuer · Disposed 7,136 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.96 · Expires 2019-12-12 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-04 · Disposition to issuer · Disposed 4,200 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.27 · Expires 2020-12-10 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-01-04 · Disposition to issuer · Disposed 8,448 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.41 · Expires 2021-12-10 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-01-04 · Disposition to issuer · Disposed 16,840 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.08 · Expires 2022-12-08 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-01-04 · Disposition to issuer · Disposed 19,616 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.62 · Expires 2023-12-07 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2017-01-04 · Disposition to issuer · Disposed 23,936 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
| Stock Options (Option to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.99 · Expires 2021-04-26 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-01-04 · Disposition to issuer · Disposed 13,460 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-01-04 · Disposition to issuer · Disposed 1,295 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-01-04 · Disposition to issuer · Disposed 625 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-01-04 · Disposition to issuer · Disposed 1,114 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2017-01-04 · Disposition to issuer · Disposed 1,905 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.
F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2017 Filed Jan 6, 2017 12:43 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 16,840 | Not disclosed Strike: $59.41 | Not disclosed |
DisclosureSEC source: 0001179110-17-000570 · edgar.xml · derivative · entry 6 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,840 shares Expires 2021-12-10 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 12:43 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerRestricted Stock Units · Derivative | 1,295 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000570 · edgar.xml · derivative · entry 5 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,295 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 12:43 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Option to Buy) · Derivative | 13,460 | Not disclosed Strike: $40.99 | Not disclosed |
DisclosureSEC source: 0001179110-17-000570 · edgar.xml · derivative · entry 4 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,460 shares Expires 2021-04-26 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 12:43 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 8,448 | Not disclosed Strike: $35.27 | Not disclosed |
DisclosureSEC source: 0001179110-17-000570 · edgar.xml · derivative · entry 3 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,448 shares Expires 2020-12-10 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 12:43 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 4,200 | Not disclosed Strike: $34.96 | Not disclosed |
DisclosureSEC source: 0001179110-17-000570 · edgar.xml · derivative · entry 2 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,200 shares Expires 2019-12-12 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 12:43 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerCommon Stock | 7,136 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000570 · edgar.xml · nonDerivative · entry 1 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:13 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionRestricted Stock Units · Derivative | 635 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-033312 · edgar.xml · derivative · entry 12 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,905 Underlying: Common Stock · 2,540 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F7 · derivative.exercise_date: The restricted stock units will vest 25% on December 17th annually beginning the date shown. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:13 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionRestricted Stock Units · Derivative | 557 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-033312 · edgar.xml · derivative · entry 11 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,114 Underlying: Common Stock · 1,671 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F7 · derivative.exercise_date: The restricted stock units will vest 25% on December 17th annually beginning the date shown. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:13 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionRestricted Stock Units · Derivative | 625 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-033312 · edgar.xml · derivative · entry 10 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F7 · derivative.exercise_date: The restricted stock units will vest 25% on December 17th annually beginning the date shown. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:13 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionRestricted Stock Units · Derivative | 264 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-033312 · edgar.xml · derivative · entry 9 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F7 · derivative.exercise_date: The restricted stock units will vest 25% on December 17th annually beginning the date shown. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:13 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Tax withholdingCommon Stock | 214 | $79.20 | $16,948.80 |
DisclosureSEC source: 0001179110-16-033312 · edgar.xml · nonDerivative · entry 8 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,136 F6 · shares: 635 shares of restricted stock vested on December 17, 2016. 214 shares were used to pay taxes and 421 shares were released Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:13 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionCommon Stock | 635 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-16-033312 · edgar.xml · nonDerivative · entry 7 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:13 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Tax withholdingCommon Stock | 188 | $79.20 | $14,889.60 |
DisclosureSEC source: 0001179110-16-033312 · edgar.xml · nonDerivative · entry 6 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,715 F5 · shares: 557 shares of restricted stock vested on December 17, 2016. 188 shares were used to pay taxes and 369 shares were released. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:13 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionCommon Stock | 557 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-16-033312 · edgar.xml · nonDerivative · entry 5 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:13 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Tax withholdingCommon Stock | 210 | $79.20 | $16,632.00 |
DisclosureSEC source: 0001179110-16-033312 · edgar.xml · nonDerivative · entry 4 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,346 F4 · shares: 625 shares of restricted stock vested on December 17, 2016. 210 shares were used to pay taxes and 415 shares were released. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:13 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionCommon Stock | 625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-16-033312 · edgar.xml · nonDerivative · entry 3 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:13 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Tax withholdingCommon Stock | 89 | $79.20 | $7,048.80 |
DisclosureSEC source: 0001179110-16-033312 · edgar.xml · nonDerivative · entry 2 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,931 F3 · shares: 264 shares of restricted stock vested on December 17, 2016. 89 shares were used to pay taxes and 175 shares were released. Read SEC document |
| December 17, 2016 Filed Dec 20, 2016 17:13 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Exercise / conversionCommon Stock | 264 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-16-033312 · edgar.xml · nonDerivative · entry 1 Murphy Mark W. · CIK 0001575293 · VP, IT and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F2 · balance_after: Includes 338 additional shares acquired through the Company Employee Stock Purchase Plan on July 31, 2015 and 83 shares accrued through the issuer's dividend reinvestment plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.